RAD51C
- Summary
- RAD51C as a novel susceptibility gene for hereditary breast and ovarian cancer.
- Technology Benefits
- RAD51C as a novel susceptibility gene for hereditary: breast cancer, ovarian cancer, head and neck squamous cell carcinomas (HNSCC).
RAD51C as companion diagnostic for PARP or TOPO I Inhibitors.
- Technology Application
- Professional societies and health care systems, risk-adapted personalized treatment, identify individuals with germline and/or somatic mutation(s) in cancer risk genes
- Detailed Technology Description
- A novel susceptibility gene for hereditary cancers. RAD51C, which encodes for a protein involved in DNA repair, has been found to be mutated in families with breast and ovarian cancer, but not in healthy control subjects
- Type of Cooperation
- Licensing
- Application Date
- 09/04/2010 00:00:00
- Application No.
- EP20100159524 20100409
- Classes
- - international:
C12Q1/68
- cooperative:
C12Q1/6886; C12Q2600/106; C12Q2600/156
- Others
- Patent application
- ID No.
- 2301
- Country/Region
- Germany
For more information, please click Here
